Literature DB >> 15269375

Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice.

Tomoki Yoshikawa1,2, Keiko Matsuo2, Kazutoshi Matsuo3, Yujiro Suzuki4, Akio Nomoto1, Shin-Ichi Tamura5,2, Takeshi Kurata2, Tetsutaro Sata2.   

Abstract

The kinetics of infectious virus (p.f.u.), total virus and virus-Ig complex formation following influenza A/PR8 (H1N1) viral infection was examined in the nasal secretions of naive mice and mice immunized with A/PR8, A/Yamagata (H1N1), A/Guizhou (H3N2) and B/Ibaraki influenza viruses. The total number of virus particles and the number within virus-Ig complexes, captured in advance using an anti-mouse Ig-coated plate, were determined on the basis of viral genome copy number using quantitative RT-PCR. The kinetics of infectious and total virus particle formation, the latter of which increased by 10(3)-10(4)-fold above infectious virus numbers, showed that virus elimination from the nasal area was earlier in A/PR8, A/Yamagata and A/Guizhou-X virus-immunized mice, in decreasing order, compared with naive mice. Early virus elimination correlated with the level of A/PR8 virus-reactive antibodies in immunized mice. Virus elimination coincided with the appearance of virus-Ig complexes shortly after infection. This result suggested that antibodies led to the formation of immune complexes in a dose-dependent manner together with a reduction in number of infectious virus particles. The fact that a large number of virus particles was observed in immune complexes for a wide range antibody levels made it difficult to detect slight differences in virus number within the immune complexes, depending on antibody level. These results suggested that the formation of virus-Ig complexes in virus-immunized mice shortly after infection is involved in early virus elimination, which is determined by the strength of protective immunity against challenge viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269375     DOI: 10.1099/vir.0.79892-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  A simple mathematical model helps to explain the immunodominance of CD8 T cells in influenza A virus infections.

Authors:  Andreas Handel; Rustom Antia
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

2.  The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses.

Authors:  Kouji Sakai; Yasushi Ami; Maino Tahara; Toru Kubota; Masaki Anraku; Masako Abe; Noriko Nakajima; Tsuyoshi Sekizuka; Kazuya Shirato; Yuriko Suzaki; Akira Ainai; Yuichiro Nakatsu; Kazuhiko Kanou; Kazuya Nakamura; Tadaki Suzuki; Katsuhiro Komase; Eri Nobusawa; Katsumi Maenaka; Makoto Kuroda; Hideki Hasegawa; Yoshihiro Kawaoka; Masato Tashiro; Makoto Takeda
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

3.  Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections.

Authors:  Weimin Zhong; Feng Liu; Libo Dong; Xiuhua Lu; Kathy Hancock; Ellis L Reinherz; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

4.  Influenza virus-induced type I interferon leads to polyclonal B-cell activation but does not break down B-cell tolerance.

Authors:  Anne Woods; Fanny Monneaux; Pauline Soulas-Sprauel; Sylviane Muller; Thierry Martin; Anne-Sophie Korganow; Jean-Louis Pasquali
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

5.  A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead.

Authors:  Catherine A A Beauchemin; Andreas Handel
Journal:  BMC Public Health       Date:  2011-02-25       Impact factor: 3.295

6.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

7.  Blood screening for influenza.

Authors:  Michael Kai Hourfar; Anna Themann; Markus Eickmann; Pilaipan Puthavathana; Thomas Laue; Erhard Seifried; Michael Schmidt
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

8.  Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load.

Authors:  Stephen M Petrie; Teagan Guarnaccia; Karen L Laurie; Aeron C Hurt; Jodie McVernon; James M McCaw
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

9.  Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Authors:  Rick A Bright; Donald M Carter; Corey J Crevar; Franklin R Toapanta; Jonathan D Steckbeck; Kelly S Cole; Niranjan M Kumar; Peter Pushko; Gale Smith; Terrence M Tumpey; Ted M Ross
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

10.  Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  PLoS Comput Biol       Date:  2007-12       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.